LAROTID
LOE ApproachingNDAORALFOR SUSPENSIONPriority Review
Approved
Jan 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAROTID is an oral suspension small-molecule drug approved by GSK in 1974 with an unknown mechanism of action and indication profile. The product is a legacy oral formulation currently approaching loss of exclusivity. Patient population and therapeutic area cannot be determined from available data.
LOE Approaching
Approaching LOE with 30% competitive pressure signals a mature, potentially consolidating brand team; roles likely focused on lifecycle extension and margin defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate limited active hiring on this product, consistent with its LOE-approaching lifecycle stage. Career opportunities are likely concentrated in defensive roles such as market access, pricing strategy, and sales efficiency rather than expansion or innovation.
Brand ManagerRegional Sales Manager
Worked on LAROTID at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.